|
Satralizumab
|
Enspryng®
|
Roche Pharma AG
|
Nervous system diseases
|
Neuromyelitis Optica Spectrum Disorder (NMOSD), ≥12 years
|
|
Empagliflozin (3)
|
Jardiance®
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Cardiovascular diseases
|
Chronic heart failure (CHF)
|
|
Tralokinumab
|
Adtralza®
|
Leo Pharma A/S
|
Skin diseases
|
Atopic Dermatitis (AD)
|
|
Angiotensin-II-Acetat
|
Giapreza®
|
La Jolla Pharmaceutical II B.V.
|
Cardiovascular diseases
|
Hypotension
|
|
Brentuximab Vedotin (6)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
ORPHAN
|
Systemic anaplastic large cell lymphoma; first-line; combination with cyclophosphamide, doxorubicin, and prednisone.
|
|
Cabozantinib (7)
|
Cometriq®
|
Ipsen Pharma GmbH
|
Oncological diseases
ORPHAN
|
Thyroid Carcinoma (MTC)
|
|
Glecaprevir / Pibrentasvir (3)
|
Maviret®
|
AbbVie Deutschland GmbH & Co. KG
|
Infectious diseases
|
Chronic hepatitis C (CHC), 3 to < 12 years of age
|
|
Nivolumab (17)
|
Opdivo®
|
Bristol-Myers Squibb GmbH & Co. KGaA
|
Oncological diseases
|
Malignant pleural mesothelioma, first-line, combination with ipilimumab
|
|
Osimertinib (4)
|
Tagrisso®
|
AstraZeneca GmbH
|
Oncological diseases
|
NSCLC, EGFR Mutation, adjuvant therapy
|
|
Elotuzumab (3)
|
Empliciti®
|
Bristol-Myers Squibb GmbH & Co. KGaA
|
Digestive system diseases
|
Multiple Myeloma (MM), at least 2 preteatments, combination with Pomalidomid and Dexamethason
|
|
Venetoclax (5)
|
Venclyxto®
|
AbbVie Deutschland GmbH & Co. KG
|
Oncological diseases
|
Acute myeloid leukemia (AML), combination therapy, first-line
|
|
Dostarlimab
|
Jemperli®
|
GlaxoSmithKline GmbH & Co. KG
|
Oncological diseases
|
Endometrial carcinoma (EC), after prior platinum-based therapy.
|
|
Tagraxofusp
|
Elzonris®
|
Stemline Therapeutics B.V.
|
Oncological diseases
ORPHAN
|
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), first line
|
|
Berotralstat
|
Orladeyo®
|
BioCryst Pharma Deutschland GmbH
|
Other diseases
|
Hereditary angioedema, prophylaxis (HAE), ≥ 12 years of age
|
|
Ponesimod
|
Ponvory®
|
Janssen-Cilag GmbH
|
Nervous system diseases
|
Relapsing Multiple Sclerosis (MS)
|
|
Ivacaftor / Tezacaftor / Elexacaftor (5)
|
Kaftrio®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis (CF), patients <12 years (heterozygous for F508del and other/unknown mutations)
|
|
Ivacaftor / Tezacaftor / Elexacaftor (4)
|
Kaftrio®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis (CF), patients ≥12 years (heterozygous for F508del and other mutations)
|
|
Ivacaftor / Tezacaftor / Elexacaftor (3)
|
Kaftrio®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis (CF), patients ≥12 years (heterozygous for F508del and Gating mutations (incl. R117H))
|
|
Ivacaftor (21)
|
Kalydeco®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis, patients ≥12 years (heterozygous for F508del and other mutation)
|
|
Ivacaftor (20)
|
Kalydeco®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis (CF), combination with Ivacaftor/Tezacaftor/Elexacaftor in patients ≥12 years (heterozygous for F508del and RF mutation)
|
|
Bosutinib (4, reassessment)
|
Bosulif®
|
Pfizer Pharma GmbH
|
Oncological diseases
|
Chronic myeloid Leukemia (CML), Ph+, first line
|
|
Enzalutamid (5)
|
Xtandi®
|
Astellas Pharma GmbH
|
Oncological diseases
|
Prostata carcinoma (mPC), metastatic, hormonsensitive
|
|
Cenobamat
|
Ontozry®
|
Angelini Pharma Deutschland GmbH
|
Nervous system diseases
|
Epilepsy, focal seizures, pretreated
|
|
Atezolizumab (9)
|
Tecentriq®
|
Roche Pharma AG
|
Oncological diseases
|
Non-small cell lung carcinoma (NSCLC), EGFR/ALK-, first-line
|
|
Ivacaftor (19)
|
Kalydeco®
|
Vertex Pharmaceuticals (Germany) GmbH
|
Metabolic diseases
ORPHAN
|
Cystic fibrosis (CF), patients <12 years (heterozygous for F508del and Gating mutation (incl. R117H))
|
|
Isatuximab (2)
|
Sarclisa®
|
Sanofi-Aventis Deutschland GmbH
|
Oncological diseases
|
Multiple myeloma (MM), pretreated, combination with Pomalidomid and Dexamethason
|
|
Isatuximab
|
Sarclisa®
|
Sanofi-Aventis Deutschland GmbH
|
Oncological diseases
|
Multiple myeloma (MM), pretreated
|
|
Lanadelumab (2, reassessment >€50m)
|
Takhzyro®
|
Takeda GmbH
|
Other diseases
ORPHAN
|
Hereditary angioedema, prophylaxis, ≥ 12 years
|
|
Onasemnogen-Abeparvovec
|
Zolgensma®
|
Novartis Gene Therapies EU Limited
|
Nervous system diseases
ORPHAN
|
5q-associated spinal musular atrpohy (SMA)
|
|
Obinutuzumab (6, reassessment >€50m)
|
Gazyvaro®
|
Roche Pharma AG
|
Oncological diseases
ORPHAN
|
Follicular lymphoma (FL), first line
|
|
Obinutuzumab (5, reassessment >€50m)
|
Gazyvaro®
|
Roche Pharma AG
|
Oncological diseases
ORPHAN
|
Chronic lymphocytic leukemia (CLL)
|
|
Obinutuzumab (4, reassessment >€50m)
|
Gazyvaro®
|
Roche Pharma AG
|
Oncological diseases
ORPHAN
|
Follicular lymphoma (FL)
|
|
Cannabidiol (5)
|
Epidyolex®
|
GW Pharmaceuticals plc
|
Other diseases
ORPHAN
|
Seizures in relation to tuberous sclerosis
|
|
Cabotegravir
|
Vocabria®
|
ViiV Healthcare GmbH
|
Infectious diseases
|
HIV-1 infection, pretreated, combination with Rilpivirin
|
|
Erenumab (2, reassessment)
|
Aimovig®
|
Novartis Pharma GmbH
|
Nervous system diseases
|
Migraine prophylaxis
|
|
Risdiplam
|
Evrysdi®
|
Roche Pharma AG
|
Musculoskeletal system diseases
ORPHAN
|
5q-assoziated spinal Muskelatrophia (SMA)
|
|
Cabozanitinib (6, Cabometyx®)
|
Cabometyx®
|
Ipsen Pharma GmbH
|
Oncological diseases
|
Renal cell carcinoma (RCC), first line, combination with Nivolumab
|
|
Nivolumab (16)
|
Opdivo®
|
Bristol-Myers Squibb GmbH & Co. KGaA
|
Oncological diseases
|
Renal cell carcinoma (RCC) , first line, combination with Cabozantinib
|
|
Rilpivirin (3, Rekambys®)
|
Rekambys®
|
ViiV Healthcare GmbH
|
Infectious diseases
|
HIV-1 infection, pretreated, combination with Cabotegravir
|
|
Atidarsagen autotemcel OTL-200
|
Libmeldy®
|
Orchard Therapeutics GmbH
|
Metabolic diseases
ORPHAN
|
Metachromatic leucodystrophia
|
|
Pemigatinib
|
Pemazyre®
|
Incyte Biosciences Germany GmbH
|
Oncological diseases
ORPHAN
|
Cholangiocarcinoma, pretreated
|
|
Nivolumab (15)
|
Opdivo®
|
Bristol-Myers Squibb GmbH & Co. KGaA
|
Oncological diseases
|
Melanoma, adjuvant therapy
|
|
Natrium-Zirkonium-Cyclosilikat
|
Lokelma®
|
AstraZeneca GmbH
|
Metabolic diseases
|
Hyperkalemia
|
|
Remdesivir
|
Veklury®
|
Gilead Sciences GmbH
|
Infectious diseases
|
COVID-19, ≥ 12 years, additional oxygen supply
|
|
Avatrombopag (2)
|
Doptelet®
|
Swedish Orphan Biovitrum GmbH
|
Hematopoietic diseases
|
Thrombocytopenia in chronic liver disease
|
|
Avatrombopag
|
Doptelet®
|
Swedish Orphan Biovitrum GmbH
|
Hematopoietic diseases
|
Immune thrombocytopenia
|
|
Fostemsavir
|
Rukobia®
|
ViiV Healthcare GmbH
|
Infectious diseases
|
HIV infection, multi-resistant
|
|
Pembrolizumab (16)
|
Keytruda®
|
MSD Sharp & Dohme GmbH
|
Oncological diseases
|
Hodgkin-Lymphoma (HL), pretreated patients, ≥ 3 years
|
|
Pembrolizumab (15)
|
Keytruda®
|
MSD Sharp & Dohme GmbH
|
Oncological diseases
|
Urothelial carcinoma (UC), first-line
|
|
Pembrolizumab (14)
|
Keytruda®
|
MSD Sharp & Dohme GmbH
|
Oncological diseases
|
Colorectal carcinoma with MSI-H or dMMR, first line
|
|
Bedaquilin (3)
|
Sirturo®
|
Janssen-Cilag GmbH
|
Infectious diseases
ORPHAN
|
Multi-resistant pulmonary tuberculosis
|
|
Imlifidase
|
Idefirix®
|
Hansa Biopharma AB
|
Other diseases
ORPHAN
|
Desensitization after kidney transplantation
|
|
Fedratinib
|
Inrebic®
|
Celgene GmbH
|
Oncological diseases
ORPHAN
|
Myelofibrosis (MF)
|
|
Tucatinib
|
Tukysa®
|
Seagen Germany GmbH
|
Oncological diseases
|
Mamma carcinoma (BC), pretreated, combination with Trastuzumab and Capecitabin
|
|
Selpercatinib
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Medullary thyroid carcinoma (MTC), pretreated
|
|
Selpercatinib (2)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Medullary thyroid carcinoma (MTC), pretreated, > 12 years
|
|
Selpercatinib (3)
|
Retsevmo®
|
Lilly Deutschland GmbH
|
Oncological diseases
|
Medullary thyroid carcinoma (MTC), pretreated with Sorafenib and/or Lenvatinib
|
|
Avelumab (4)
|
Bavencio®
|
Merck Serono GmbH und Pfizer Pharma GmbH
|
Oncological diseases
|
Urothelial carcinoma (UC), first line
|
|
Esketamin (2)
|
Spravato®
|
Janssen-Cilag GmbH
|
Mental illnesses
|
Depression, therapy resistent, in combination with SSRI or SNRI
|
|
Esketamin
|
Spravato®
|
Janssen-Cilag GmbH
|
Mental illnesses
|
Depression, acute treatment, combination therapy
|
|
Beclometason / Formoterol / Glycopyrronium
|
Trimbow®
|
Chiesi GmbH
|
Respiratory system diseases
|
Asthma
|
|
Baloxavir marboxil (2)
|
Xofluza®
|
Roche Pharma AG
|
Infectious diseases
|
Influenza prophylaxis
|
|
Baloxavir marboxil
|
Xofluza®
|
Roche Pharma AG
|
Infectious diseases
|
Influenza
|
|
Autologe Anti-CD19-transduzierte CD3-positive Zellen
|
Tecartus®
|
Gilead Sciences GmbH
|
Oncological diseases
ORPHAN
|
Mantle cell lymphoma (MCL), pretreated
|
|
Acalabrutinib (3)
|
Calquence®
|
AstraZeneca GmbH
|
Oncological diseases
|
Chronic lymphocytic leukemia (CLL), pretreated
|
